Genetic variation in angiotensin II type 2 receptor gene influences extent of left ventricular hypertrophy in hypertrophic cardiomyopathy independent of blood pressure

Abstract

Introduction. Hypertrophic cardiomyopathy (HCM), an inherited primary cardiac disorder mostly caused by defective sarcomeric proteins, serves as a model to investigate left ventricular hypertrophy (LVH). HCM manifests extreme variability in the degree and distribution of LVH, even in patients with the same causal mutation. Genes coding for renin—angiotensin—aldosterone system components have been studied as hypertrophy modifiers in HCM, with emphasis on the angiotensin (Ang) II type 1 receptor (AT₁R). However, Ang II binding to Ang II type 2 receptors (AT₂R) also has hypertrophy-modulating effects.

Methods. We investigated the effect of the functional +1675 G/A polymorphism (rs1403543) and additional single nucleotide polymorphisms in the 3’ untranslated region of the AT₂R gene (AGTR2) on a heritable composite hypertrophy score in an HCM family cohort in which HCM founder mutations segregate.

Results. We find significant association between rs1403543 and hypertrophy, with each A allele decreasing the average wall thickness by ~0.5 mm, independent of the effects of the primary HCM causal mutation, blood pressure and other hypertrophy covariates (p = 0.020).

Conclusion. This study therefore confirms a hypertrophy-modulating effect for AT₂R also in HCM and implies that +1675 G/A could potentially be used in a panel of markers that profile a genetic predisposition to LVH in HCM.

Keywords

Angiotensin II type 2 receptor cardiac hypertrophy hypertrophic cardiomyopathy renin—angiotensin—aldosterone system

Get full access to this article

View all access options for this article.

References

Watkins H. , Seidman JG and Seidman CE Familial hypertrophic cardiomyopathy: a genetic model of cardiac hypertrophy . Hum Mol Genet 1995; 4(Spec No): 1721-1727.

Alcalai R. , Seidman JG and Seidman CE Genetic basis of hypertrophic cardiomyopathy: from bench to the clinics. J Cardiovasc Electrophysiol 2008; 19: 104-110.

Revera M. , van der Merwe L. , Heradien M. , GoosenA, Corfield VA , Brink PA , et al. Troponin T and beta-myosin mutations have distinct cardiac functional effects in hypertrophic cardiomyopathy patients without hypertrophy. Cardiovasc Res 2008; 77: 687-694.

Fananapazir L. and Epstein ND Genotype-phenotype correlations in hypertrophic cardiomyopathy. Insights provided by comparisons of kindreds with distinct and identical beta-myosin heavy chain gene mutations. Circulation 1994; 89: 22-32.

Posen BM , Moolman JC , Corfield VA and Brink PA Clinical and prognostic evaluation of familial hypertrophic cardiomyopathy in two South African families with different cardiac beta myosin heavy chain gene mutations. Br Heart J 1995; 74: 40-46.

Semsarian C. , Healey MJ , Fatkin D. , Giewat M. , Duffy C. , Seidman CE , et al. A polymorphic modifier gene alters the hypertrophic response in a murine model of familial hypertrophic cardiomyopathy . J Mol Cell Cardiol 2001; 33: 2055-2060.

Kaufman BD , Auerbach S. , Reddy S. , Manlhiot C. , Deng L. , Prakash A. , et al. RAAS gene polymorphisms influence progression of pediatric hypertrophic cardiomyopathy. Hum Genet 2007; 122: 515-523.

Ortlepp JR , Vosberg HP , Reith S. , Ohme F. , Mahon NG , Schroder D. , et al. Genetic polymorphisms in the renin- angiotensin-aldosterone system associated with expression of left ventricular hypertrophy in hypertrophic cardiomyopathy: a study of five polymorphic genes in a family with a disease-causing mutation in the myosin binding protein C gene. Heart 2002; 87: 270-275.

Perkins MJ , Van Driest SL , Ellsworth EG , Will ML , Gersh BJ , Ommen SR , et al. Gene-specific modifying effects of pro-LVH polymorphisms involving the renin- angiotensin-aldosterone system among 389 unrelated patients with hypertrophic cardiomyopathy. Eur Heart J 2005 ; 26: 2457-2462.

10.

Hoffmann S. , Krause T. , van Geel PP , Willenbrock R. , Pagel I. , Pinto YM , et al. Overexpression of the human angiotensin II type 1 receptor in the rat heart augments load induced cardiac hypertrophy. J Mol Med 2001; 79: 601-608.

11.

Dahlof B. , Devereux RB , Kjeldsen SE , Julius S. , Beevers G. , de Faire U. , et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.

12.

Okin PM , Devereux RB , Jern S. , Kjeldsen SE , Julius S. , Nieminen MS , et al. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study. Circulation 2003; 108: 684-690.

13.

Bartunek J. , Weinberg EO , Tajima M. , Rohrbach S. and Lorell BH Angiotensin II type 2 receptor blockade amplifies the early signals of cardiac growth response to angiotensin II in hypertrophied hearts. Circulation 1999; 99: 22-25.

14.

Mukawa H. , Toki Y. , Miyazaki Y. , Matsui H. , Okumura K. and Ito T. Angiotensin II type 2 receptor blockade partially negates antihypertrophic effects of type 1 receptor blockade on pressure-overload rat cardiac hypertrophy . Hypertens Res 2003; 26: 89-95.

15.

Alfakih K. , Maqbool A. , Sivananthan M. , Walters K. , Bainbridge G. , Ridgway J. , et al. Left ventricle mass index and the common, functional, X-linked angiotensin II type-2 receptor gene polymorphism (-1332 G/A) in patients with systemic hypertension. Hypertension 2004; 43: 1189-1194.

16.

Schmieder RE , Erdmann J. , Delles C. , Jacobi J. , Fleck E. , Hilgers K. , et al. Effect of the angiotensin II type 2-receptor gene (+1675 G/A) on left ventricular structure in humans. J Am Coll Cardiol 2001; 37: 175-182.

17.

Herrmann SM , Nicaud V. , Schmidt-Petersen K. , Pfeifer J. , Erdmann J. , McDonagh T. , et al. Angiotensin II type 2 receptor gene polymorphism and cardiovascular phenotypes: the GLAECO and GLAOLD studies. Eur J Heart Fail 2002; 4: 707-712.

18.

Balmforth AJ Angiotensin II type 2 receptor gene polymorphisms in cardiovascular disease. J Renin Angiotensin Aldosterone Syst 2010; 11: 79-85.

19.

Deinum J. , van Gool JM , Kofflard MJ , ten Cate FJ and Danser AH Angiotensin II type 2 receptors and cardiac hypertrophy in women with hypertrophic cardiomyopathy. Hypertension 2001; 38: 1278-1281.

20.

Moolman-Smook JC , De Lange WJ , Bruwer EC , Brink PA and Corfield VA The origins of hypertrophic cardiomyopathy-causing mutations in two South African subpopulations: a unique profile of both independent and founder events. Am J Hum Genet 1999; 65: 1308-1320.

21.

Schiller NB , Shah PM , Crawford M. , DeMaria A. , Devereux R. , Feigenbaum H. , et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989 ; 2: 358-367.

22.

Wigginton JE and Abecasis GR PEDSTATS: descriptive statistics, graphics and quality assessment for gene mapping data. Bioinformatics 2005; 21: 3445-3447.

23.

Barrett JC , Fry B. , Maller J. and Daly MJ Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-265.

24.

Pilia G. , Chen WM , Scuteri A. , Orru M. , Albai G. , Dei M. , et al. Heritability of cardiovascular and personality traits in 6,148 Sardinians. Plos Genetics 2006; 2: 1207-1223.

25.

Abecasis GR , Cardon LR and Cookson WO A general test of association for quantitative traits in nuclear families. Am J Hum Genet 2000; 66: 279-292.

26.

Erdmann J. , Guse M. , Kallisch H. , Fleck E. and Regitz-Zagrosek V. Novel intronic polymorphism (+1675G/A) in the human angiotensin II subtype 2 receptor gene. Hum Mutat 2000; 15: 487.

27.

Nishimura H. , Yerkes E. , Hohenfellner K. , Miyazaki Y. , Ma J. , Hunley TE , et al. Role of the angiotensin type 2 receptor gene in congenital anomalies of the kidney and urinary tract, CAKUT, of mice and men. Mol Cell 1999; 3: 1-10.

28.

Warnecke C. , Mugrauer P. , Surder D. , Erdmann J. , Schubert C. and Regitz-Zagrosek V. Intronic ANG II type 2 receptor gene polymorphism 1675 G/A modulates receptor protein expression but not mRNA splicing. Am J Physiol Regul Integr Comp Physiol 2005; 289: R1729-R1735.

29.

Myerson SG , Montgomery HE , World MJ and Pennell DJ Left ventricular mass: reliability of M-mode and 2-dimensional echocardiographic formulas. Hypertension 2002; 40: 673-678.

30.

Mayosi BM , Keavney B. , Watkins H. and Farrall M. Measured haplotype analysis of the aldosterone synthase gene and heart size . Eur J Hum Genet 2003; 11: 395-401.

31.

Van der Merwe L. , Cloete R. , Revera M. , Heradien M. , Goosen A. , Corfield VA , et al. Genetic variation in angiotensin-converting enzyme 2 gene is associated with extent of left ventricular hypertrophy in hypertrophic cardiomyopathy. Hum Genet 2008 ; 124: 57-61.

32.

Allison JD , Flickinger FW , Wright JC , Falls DG, III , Prisant LM , Von Dohlen TW , et al. Measurement of left ventricular mass in hypertrophic cardiomyopathy using MRI: comparison with echocardiography. Magn Reson Imaging 1993; 11: 329-334.